1. Impact of disease-modifying treatments on humoral response after COVID-19 vaccination: A mirror of the response after SARS-CoV-2 infection
- Author
-
Kévin Bigaut, L. Kremer, L. Lanotte, Marie-Céline Fleury, Nicolas Collongues, and J. de Seze
- Subjects
COVID-19 Vaccines ,medicine.drug_class ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Disease ,Monoclonal antibody ,Serology ,Multiple sclerosis ,03 medical and health sciences ,0302 clinical medicine ,Clinical endpoint ,medicine ,Humans ,030212 general & internal medicine ,Humoral response ,Antibody ,biology ,business.industry ,SARS-CoV-2 ,Vaccination ,COVID-19 ,medicine.disease ,Neurology ,Immunology ,biology.protein ,Original Article ,Neurology (clinical) ,business ,Vaccine ,030217 neurology & neurosurgery - Abstract
OBJECTIVE: To analyze the humoral response after COVID-19 vaccination in patients with multiple sclerosis (MS) according to disease-modifying treatments (DMTs) and in comparison with the humoral response after SARS-CoV-2 infection. METHODS: We included 28 MS patients with serological results after COVID-19 vaccination (Pfizer-BioNTech or Moderna ARNm) and 61 MS patients with serological results after COVID-19 (COVID-19 group) among patients followed up at the MS Center of Strasbourg, France, between January and April 2021. The primary endpoint was the IgG index according to DMTs (anti-CD20 mAb, sphingosine 1-phosphate receptor [S1PR] modulator and other treatments) and COVID-19 vaccine or COVID-19 groups. RESULTS: In the vaccinated MS patients, the median IgG index was lower in patients treated with anti-CD20 mAb and in patients treated with S1PR modulator compared to patients receiving other or no DMTs (4.80 [1.58-28.6], 16.5 [16.3-48.5], 1116 [434-1747] and 1272 [658-1886], respectively, P
- Published
- 2021